Trial · NCT06860633
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 20
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in the Quantitative Myasthenia Gravis (QMG) score at day 11 | Baseline, Day 11 | The Quantitative Myasthenia Gravis (QMG) is a scoring system that quantifies disease severity by measuring ocular, bulbar, respiratory and limb strength. The total scores range from 0 to 39, with higher scores indicating greater disease severity. |
| Secondary | Percentage of participants requiring rescue therapy with Plasma Exchange (PLEX) or Intravenous Immunoglobulin (IVIG) | During hospitalization, approximately 7 days | Number of participants requiring rescue therapy with Plasma Exchange (PLEX) or Intravenous Immunoglobulin (IVIG) over number of total participants |
| Secondary | Change from baseline in Myasthenia Gravis Activities of Daily Life (MG-ADL) scale at day 18 | Baseline, Day 18 | The Myasthenia Gravis Activities of Daily Life (MG-ADL) is a questionnaire administered verbally that measures MG symptoms and functional activities related to activities of daily living. The summative total scores range from 0 to 24, with higher scores indicating greater disease severity. |
| Secondary | Change from baseline in Myasthenia Gravis Activities of Daily Life (MG-ADL) scale at day 32 | Baseline, Day 32 | The Myasthenia Gravis Activities of Daily Life (MG-ADL) is a questionnaire administered verbally that measures MG symptoms and functional activities related to activities of daily living. The summative total scores range from 0 to 24, with higher scores indicating greater disease severity. |
| Secondary | Change from baseline in Myasthenia Gravis Manual Muscle Test (MG-MMT) at day 11 | Baseline, Day 11 | The Myasthenia Gravis Manual Muscle Test (MG-MMT) is an assessment that assigns numerical values to the presence of mild, moderate or severe weakness for specific muscle groups that may be affected by MG. The summative total scores range from 0 to 120, with higher scores indicating greater disease severity. |
| Secondary | Change from baseline in Myasthenia Gravis Manual Muscle Test (MG-MMT) at day 18 | Baseline, Day 18 | The Myasthenia Gravis Manual Muscle Test (MG-MMT) is an assessment that assigns numerical values to the presence of mild, moderate or severe weakness for specific muscle groups that may be affected by MG. The summative total scores range from 0 to 120, with higher scores indicating greater disease severity. |
| Secondary | Change from baseline in Myasthenia Gravis Manual Muscle Test (MG-MMT) at day 32 | Baseline, Day 32 | The Myasthenia Gravis Manual Muscle Test (MG-MMT) is an assessment that assigns numerical values to the presence of mild, moderate or severe weakness for specific muscle groups that may be affected by MG. The summative total scores range from 0 to 120, with higher scores indicating greater disease severity. |
| Secondary | Change from baseline in Myasthenia Gravis Quality of Life-15 Revised (MG-QOL15r) at day 18 | Baseline, Day 18 | The Myasthenia Gravis Quality of Life-15 Revised (MG-QOL15r) is a scale that measures perceived limitations to fifteen different activities due to MG. Individual items are score 0 (not at all) to 4 (quite a bit). The summative total scores range from 0 to 60, with higher scores representing worse quality of life. |
| Secondary | Change from baseline in Myasthenia Gravis Quality of Life-15 Revised (MG-QOL15r) at day 32 | Baseline, Day 32 | The Myasthenia Gravis Quality of Life-15 Revised (MG-QOL15r) is a scale that measures perceived limitations to fifteen different activities due to MG. Individual items are score 0 (not at all) to 4 (quite a bit). The summative total scores range from 0 to 60, with higher scores representing worse quality of life. |
| Secondary | Change from baseline in the Quantitative Myasthenia Gravis (QMG) score at day 4 | Baseline, Day 4 | The Quantitative Myasthenia Gravis (QMG) is a scoring system that quantifies disease severity by measuring ocular, bulbar, respiratory and limb strength. The total scores range from 0 to 39, with higher scores indicating greater disease severity. |
| Secondary | Change from baseline in the Quantitative Myasthenia Gravis (QMG) score at day 32 | Baseline, Day 32 | The Quantitative Myasthenia Gravis (QMG) is a scoring system that quantifies disease severity by measuring ocular, bulbar, respiratory and limb strength. The total scores range from 0 to 39, with higher scores indicating greater disease severity. |
| Secondary | Postinterventional status at day 11 | Day 11 | Postinterventional status is an assessment of whether a participant's MG symptoms/signs have remained unchanged, worsened, improved or reached minimal manifestations or minimal symptom expression. |
| Secondary | Postinterventional status at day 18 | Day 18 | Postinterventional status is an assessment of whether a participant's MG symptoms/signs have remained unchanged, worsened, improved or reached minimal manifestations or minimal symptom expression. |
| Secondary | Postinterventional status at day 32 | Day 32 | Postinterventional status is an assessment of whether a participants's MG symptoms/signs have remained unchanged, worsened, improved or reached minimal manifestations or minimal symptom expression. |
| Secondary | Length of hospital stay | Duration of hospitalization, approximately 7 days | Length of time between the participant being admitted to discharged. For participants transferred to University of Colorado Hospital, the time of admission/presentation to the outside hospital is counted. |
| Secondary | Proportion of participants requiring mechanical ventilation | During hospitalization, approximately 7 days | Number of participants requiring mechanical ventilation against the total number of participants. |
| Secondary | Proportion of participants requiring enteral feeding | During hospitalization, approximately 7 days | Number of participants requiring enteral feeding (such as an NG tube or PEG tube) against the total number of participants. |
| Secondary | Time to freedom from respiratory support | During hospitalization, approximately 7 days | Length of time between the participant being put on respiratory support (e.g. ventilator, BiPAP) and respiratory support being discontinued. |
| Secondary | Change from baseline in Total Immunoglobin G (IgG) at day 32 | Baseline, Day 32 | Immunoglobin G (IgG) total level will be measured via blood collection. |
| Secondary | Change from baseline in Acetylcholine Receptor (AchR) antibody titer at day 32 | Baseline, Day 32 | Acetylcholine Receptor (AchR) antibody titer will be measured via blood collection. |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06860633/registered